Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Head-to-Head comparison of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Low dose radiotherapy-induced tumor-preferential antigens enhance antibody-drug conjugate efficacy in solid tumors.Neoplasia (New York, N.Y.) · 2026Article
- Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics.Exploration of targeted anti-tumor therapy · 2026Review
- Kinesin Family Member 26A Disrupts DNA-Dependent Protein Kinase Complex Formation to Enhance Chemoradiotherapy Sensitivity in Colorectal Cancer.International journal of biological sciences · 2026Article
- Precision epigenetic therapies in oncology.Cancer metastasis reviews · 2025Review
- Engineering Lipid-Polymer Nanoparticles for siRNA Delivery to Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
- [18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer.Molecular imaging and biology · 2025Article
- The Role of [Cancers · 2025Review
- [EJNMMI research · 2025Article
- Innovative Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with Various Pathway Signaling.International journal of molecular and cellular medicine · 2025Review
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal transduction and targeted therapy · 2024Review
- Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories.Biomolecules · 2023Review
- [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.Surgical oncology clinics of North America · 2022Review
- Novel applications of molecular imaging to guide breast cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Review
- Recent advances in epigenetic anticancer therapeutics and future perspectives.Frontiers in genetics · 2022Review
- Vorinostat (SAHA) and Breast Cancer: An Overview.Cancers · 2021Review
- Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
Histone deacetylase inhibitors (HDACIs) may overcome endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. We tested whether
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.